Copyright © 2012 Eleftheria Tsakalozou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. F. Stegmeier, M. Warmuth, W. R. Sellers, and M. Dorsch, “Targeted cancer therapies in the twenty-first century: lessons from imatinib,” Clinical Pharmacology and Therapeutics, vol. 87, no. 5, pp. 543–552, 2010. View at Publisher · View at Google Scholar · View at Scopus
2. D. Farrell, K. Ptak, N. J. Panaro, and P. Grodzinski, “Nanotechnology-based cancer therapeutics—promise and challenge—lessons learned through the NCI alliance for nanotechnology in cancer,” Pharmaceutical Research, vol. 28, no. 2, pp. 273–278, 2011. View at Publisher · View at Google Scholar · View at Scopus
3. J. H. Atkins and L. J. Gershell, “Selective anticancer drugs. Market indicators,” Nature Reviews Drug Discovery, vol. 1, no. 7, pp. 491–492, 2002. View at Scopus
4. Y. Wu, J. E. Rosenberg, and M. E. Taplin, “Novel agents and new therapeutics in castration-resistant prostate cancer,” Current Opinion in Oncology, vol. 23, no. 3, pp. 290–296, 2011. View at Publisher · View at Google Scholar · View at Scopus
5. M. J. Vicent, H. Ringsdorf, and R. Duncan, “Polymer therapeutics: clinical applications and challenges for development,” Advanced Drug Delivery Reviews, vol. 61, no. 13, pp. 1117–1120, 2009. View at Publisher · View at Google Scholar · View at Scopus
6. Y. Bae and K. Kataoka, “Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers,” Advanced Drug Delivery Reviews, vol. 61, no. 10, pp. 768–784, 2009. View at Publisher · View at Google Scholar · View at Scopus
7. K. S. M. Smalley, N. K. Haass, P. A. Brafford, M. Lioni, K. T. Flaherty, and M. Herlyn, “Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases,” Molecular Cancer Therapeutics, vol. 5, no. 5, pp. 1136–1144, 2006. View at Publisher · View at Google Scholar · View at Scopus
8. M. Görn, C. R. Habermann, M. Anige et al., “A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC),” Onkologie, vol. 31, no. 4, pp. 185–189, 2008. View at Publisher · View at Google Scholar · View at Scopus
9. A. Grattoni, H. Shen, D. Fine et al., “Nanochannel technology for constant delivery of chemotherapeutics: beyond metronomic administration,” Pharmaceutical Research, vol. 28, no. 2, pp. 292–300, 2011. View at Publisher · View at Google Scholar · View at Scopus
10. H. C. Shin, A. W. G. Alani, H. Cho, Y. Bae, J. M. Kolesar, and G. S. Kwon, “A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs,” Molecular Pharmaceutics, vol. 8, no. 4, pp. 1257–1265, 2011. View at Publisher · View at Google Scholar · View at Scopus
11. G. W. Stone, S. Barzee, V. Snarsky et al., “Nanoparticle-delivered multimeric soluble CD40L DNA combined with toll-like receptor agonists as a treatment for melanoma,” PLoS ONE, vol. 4, no. 10, Article ID e7334, 2009. View at Publisher · View at Google Scholar · View at Scopus
12. I. Skidan, B. Miao, R. V. Thekkedath, P. Dholakia, A. Degterev, and V. Torchilin, “In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL,” Drug Delivery, vol. 16, no. 1, pp. 45–51, 2009. View at Publisher · View at Google Scholar · View at Scopus
13. K. J. Pienta, “Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer,” Seminars in Oncology, vol. 28, no. 4, pp. 3–7, 2001. View at Scopus
14. N. J. Mackler and K. J. Pienta, “Drug insight: use of docetaxel in prostate and urothelial cancers,” Nature Clinical Practice Urology, vol. 2, no. 2, pp. 92–100, 2005. View at Publisher · View at Google Scholar · View at Scopus
15. C. A. Stein, “Mechanisms of action of taxanes in prostate cancer,” Seminars in Oncology, vol. 26, no. 5, pp. 3–7, 1999. View at Scopus
16. S. Haldar, J. Chintapalli, and C. M. Croce, “Taxol induces bcl-2 phosphorylation and death of prostate cancer cells,” Cancer Research, vol. 56, no. 6, pp. 1253–1255, 1996. View at Scopus
17. G. Capranico and M. Binaschi, “DNA sequence selectivity of topoisomerases and topoisomerase poisons,” Biochimica et Biophysica Acta, vol. 1400, no. 1–3, pp. 185–194, 1998. View at Publisher · View at Google Scholar · View at Scopus
18. S. Moro, G. L. Beretta, D. Dal Ben, J. Nitiss, M. Palumbo, and G. Capranico, “Interaction model for anthracycline activity against DNA topoisomerase II,” Biochemistry, vol. 43, no. 23, pp. 7503–7513, 2004. View at Publisher · View at Google Scholar · View at Scopus
19. Y. Pommier, E. Leo, H. Zhang, and C. Marchand, “DNA topoisomerases and their poisoning by anticancer and antibacterial drugs,” Chemistry and Biology, vol. 17, no. 5, pp. 421–433, 2010. View at Publisher · View at Google Scholar · View at Scopus
20. H. S. Kim, Y. S. Lee, and D. K. Kim, “Doxorubicin exerts cytotoxic effects through cell cycle arrest and fas-mediated cell death,” Pharmacology, vol. 84, no. 5, pp. 300–309, 2009. View at Publisher · View at Google Scholar · View at Scopus
21. A. Van Bokhoven, M. Varella-Garcia, C. Korch et al., “Molecular characterization of human prostate carcinoma cell lines,” Prostate, vol. 57, no. 3, pp. 205–225, 2003. View at Publisher · View at Google Scholar · View at Scopus
22. K. R. Stone, D. D. Mickey, and H. Wunderli, “Isolation of a human prostate carcinoma cell line (DU 145),” International Journal of Cancer, vol. 21, no. 3, pp. 274–281, 1978. View at Scopus
23. M. E. Kaighn, K. Shankar Narayan, and Y. Ohnuki, “Establishment and characterization of a human prostatic carcinoma cell line (PC-3),” Investigative Urology, vol. 17, no. 1, pp. 16–23, 1979. View at Scopus
24. M. D. Galsky and N. J. Vogelzang, “Docetaxel-based combination therapy for castration-resistant prostate cancer,” Annals of Oncology, vol. 21, no. 11, pp. 2135–2144, 2010. View at Publisher · View at Google Scholar · View at Scopus
25. G. Di Lorenzo, C. Buonerba, R. Autorino, S. De Placido, and C. N. Sternberg, “Castration-resistant prostate cancer: current and emerging treatment strategies,” Drugs, vol. 70, no. 8, pp. 983–1000, 2010. View at Publisher · View at Google Scholar · View at Scopus
26. Y. Kageyama, “Development of drugs against hormone-refractory prostate cancer,” Drug Development Research, vol. 69, no. 7, pp. 431–450, 2008. View at Publisher · View at Google Scholar · View at Scopus
27. N. Mottet, J. Bellmunt, M. Bolla et al., “EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer,” European Urology, vol. 59, no. 4, pp. 572–583, 2011. View at Publisher · View at Google Scholar · View at Scopus
28. E. M. Basch, M. R. Somerfield, T. M. Beer et al., “American society of clinical oncology endorsement of the cancer care ontario practice guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5313–5318, 2007. View at Publisher · View at Google Scholar · View at Scopus
29. H. I. Scher, S. Halabi, I. Tannock et al., “Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group,” Journal of Clinical Oncology, vol. 26, no. 7, pp. 1148–1159, 2008. View at Publisher · View at Google Scholar · View at Scopus
30. V. E. Chiuri, N. Silvestris, A. Tinelli, and V. Lorusso, “Efficacy and safety of the combination of docetaxel (Taxotere®) with targeted therapies in the treatment of solid malignancies,” Current Drug Targets, vol. 10, no. 10, pp. 982–1000, 2009. View at Publisher · View at Google Scholar · View at Scopus
31. W. D. DeWys, C. B. Begg, and H. Brodovsky, “A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response,” Prostate, vol. 4, no. 1, pp. 1–11, 1983. View at Scopus
32. C. Kouroussis, N. Androulakis, L. Vamvakas et al., “Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors,” Oncology, vol. 69, no. 3, pp. 202–207, 2005. View at Publisher · View at Google Scholar · View at Scopus
33. B. Neri, G. Cipriani, C. Fulignati et al., “Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: report of a phase II trial,” Anti-Cancer Drugs, vol. 16, no. 1, pp. 63–66, 2005. View at Publisher · View at Google Scholar · View at Scopus
34. B. Neri, E. Molinara, P. Pantaleo et al., “Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma,” Oncology Research, vol. 17, no. 11-12, pp. 565–570, 2009. View at Scopus
35. R. Petrioli, L. Paolelli, E. Francini, A. Manganelli, F. Salvestrini, and G. Francini, “Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer,” Urology, vol. 69, no. 1, pp. 142–146, 2007. View at Publisher · View at Google Scholar · View at Scopus
36. D. P. Petrylak, C. M. Tangen, M. H. A. Hussain et al., “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer,” New England Journal of Medicine, vol. 351, no. 15, pp. 1513–1520, 2004. View at Publisher · View at Google Scholar · View at Scopus
37. I. F. Tannock, R. De Wit, W. R. Berry et al., “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer,” New England Journal of Medicine, vol. 351, no. 15, pp. 1502–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
38. D. P. Petrylak, “Docetaxel for the treatment of hormone-refractory prostate cancer,” Reviews in Urology, vol. 5, supplement 2, pp. S14–S21, 2003.
39. V. J. Sinibaldi, M. A. Carducci, S. Moore-Cooper, M. Laufer, M. Zahurak, and M. A. Eisenberger, “Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma,” Cancer, vol. 94, no. 5, pp. 1457–1465, 2002. View at Publisher · View at Google Scholar · View at Scopus
40. D. M. Savarese, S. Halabi, and V. Hars, “Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B,” Journal of Clinical Oncology, vol. 19, no. 9, pp. 2509–2516, 2001.
41. S. Zeng, Y. Z. Chen, L. Fu, K. R. Johnson, and W. Fan, “In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells,” Clinical Cancer Research, vol. 6, no. 9, pp. 3766–3773, 2000. View at Scopus
42. J. O'Shaughnessy, D. Miles, S. Vukelia et al., “Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results,” Journal of Clinical Oncology, vol. 20, no. 12, pp. 2812–2823, 2002. View at Publisher · View at Google Scholar · View at Scopus
43. D. R. Budman, A. Calabro, and W. Kreis, “Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro,” Anti-Cancer Drugs, vol. 13, no. 10, pp. 1011–1016, 2002. View at Publisher · View at Google Scholar · View at Scopus
44. A. Awada, J. Albanell, P. A. Canney et al., “Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study,” British Journal of Cancer, vol. 98, no. 9, pp. 1500–1507, 2008. View at Publisher · View at Google Scholar · View at Scopus
45. T. C. Chou, “Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies,” Pharmacological Reviews, vol. 58, no. 3, pp. 621–681, 2006. View at Publisher · View at Google Scholar · View at Scopus
46. T. C. Chou, “Preclinical versus clinical drug combination studies,” Leukemia and Lymphoma, vol. 49, no. 11, pp. 2059–2080, 2008. View at Publisher · View at Google Scholar · View at Scopus
47. A. C. Pinto, J. N. Moreira, and S. Simoes, “Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.,” Cancer Chemotherapy and Pharmacology, vol. 64, no. 3, pp. 445–454, 2009. View at Publisher · View at Google Scholar
48. S. A. Ahmed, R. M. Gogal Jr, and J. E. Walsh, “A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay,” Journal of Immunological Methods, vol. 170, no. 2, pp. 211–224, 1994. View at Publisher · View at Google Scholar · View at Scopus
49. R. D. Fields and M. V. Lancaster, “Dual-attribute continuous monitoring of cell proliferation/cytotoxicity,” American Biotechnology Laboratory, vol. 11, no. 4, pp. 48–50, 1993. View at Scopus
50. A. Heidenreich, F. Sommer, C. H. Ohlmann et al., “Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma,” Cancer, vol. 101, no. 5, pp. 948–956, 2004. View at Publisher · View at Google Scholar · View at Scopus
51. R. McMenemin, G. Macdonald, L. Moffat, and D. Bissett, “A phase II study of Caelyx™ (liposomal doxorubicin) in metastatic carcinoma of the prostate: tolerability and efficacy modification by liposomal encapsulation,” Investigational New Drugs, vol. 20, no. 3, pp. 331–337, 2002. View at Publisher · View at Google Scholar · View at Scopus
52. S. D. Fossa, T. Urnes, and O. Kaalhus, “Weekly low-dose adriamycin in hormone-resistant metastatic cancer of the prostate,” Scandinavian Journal of Urology and Nephrology, vol. 21, no. 1, pp. 13–16, 1987. View at Scopus
53. H. Scher, A. Yagoda, and R. C. Watson, “Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma,” Journal of Urology, vol. 131, no. 6, pp. 1099–1102, 1984. View at Scopus
54. H. Hernández-Vargas, J. Palacios, and G. Moreno-Bueno, “Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis,” Oncogene, vol. 26, no. 20, pp. 2902–2913, 2007. View at Publisher · View at Google Scholar · View at Scopus
55. D. L. Morse, H. Gray, C. M. Payne, and R. J. Gillies, “Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells,” Molecular Cancer Therapeutics, vol. 4, no. 10, pp. 1495–1504, 2005. View at Publisher · View at Google Scholar · View at Scopus
56. F. Fabbri, D. Amadori, S. Carloni et al., “Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells,” Journal of Cellular Physiology, vol. 217, no. 2, pp. 494–501, 2008. View at Publisher · View at Google Scholar · View at Scopus
57. F. Fabbri, S. Carloni, G. Brigliadori, W. Zoli, R. Lapalombella, and M. Marini, “Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study,” BMC Cell Biology, vol. 7, no. 6, pp. 1–14, 2006. View at Publisher · View at Google Scholar · View at Scopus
58. B. Fulton and C. M. Spencer, “Docetaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer,” Drugs, vol. 51, no. 6, pp. 1075–1092, 1996. View at Scopus
59. A. Hurria, M. T. Fleming, S. D. Baker et al., “Pharmacokinetics and toxicity of weekly docetaxel in older patients,” Clinical Cancer Research, vol. 12, no. 20, pp. 6100–6105, 2006. View at Publisher · View at Google Scholar · View at Scopus
60. K. Chatterjee, J. Zhang, N. Honbo, and J. S. Karliner, “Doxorubicin cardiomyopathy,” Cardiology, vol. 115, no. 2, pp. 155–162, 2010. View at Publisher · View at Google Scholar · View at Scopus
61. D. A. Gewirtz, “A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin,” Biochemical Pharmacology, vol. 57, no. 7, pp. 727–741, 1999. View at Publisher · View at Google Scholar · View at Scopus
62. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity,” Pharmacological Reviews, vol. 56, no. 2, pp. 185–229, 2004. View at Publisher · View at Google Scholar · View at Scopus
63. R. Colombo, A. Necco, G. Vailati, and A. Milzani, “Dose-dependence of doxorubicin effect on actin assembly in vitro,” Experimental and Molecular Pathology, vol. 49, no. 3, pp. 297–304, 1988. View at Scopus
64. A. Molinari, A. Calcabrini, P. Crateri, and G. Arancia, “Interaction of anthracyclinic antibiotics with cytoskeletal components of cultured carcinoma cells (CG5),” Experimental and Molecular Pathology, vol. 53, no. 1, pp. 11–33, 1990. View at Publisher · View at Google Scholar · View at Scopus
65. A. Gabizon, H. Shmeeda, and Y. Barenholz, “Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies,” Clinical Pharmacokinetics, vol. 42, no. 5, pp. 419–436, 2003. View at Publisher · View at Google Scholar · View at Scopus
66. A. Hubert, O. Lyass, D. Pode, and A. Gabizon, “Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer,” Anti-Cancer Drugs, vol. 11, no. 2, pp. 123–127, 2000. View at Publisher · View at Google Scholar · View at Scopus